Background: Serum sex hormone-binding globulin levels have been associated with mortality in adult men with type 2 diabetes (T2DM). Objectives: To confirm the association of serum sex hormone-binding globulin with mortality and then determine whether this association is mediated by age and total testosterone concentration. Materials and Methods: We studied 364 men (median age: 66 years) with T2DM over a median follow-up of 4.3 years using the Cox regression to study associations between sex hormone-binding globulin, age, total testosterone, and mortality. Results: Mortality was significantly and independently associated with sex hormone-binding globulin, age, and total testosterone. In pairwise combinations of age and sex hormone-binding globulin dichotomized by median values, the association of sex hormonebinding globulin with mortality was age-dependent. Relative to the combination of age >66 years/SHBG >35 nmol/L (mortality 22.5%), the other combinations were associated with significantly less mortality (mortality in men ≤66 years/SHBG ≤ 35 nmol/L was 3.23%). In men >66 years, SHBG ≤ 35 nmol/L was associated with decreased mortality (HR: 0.41, p = 0.037) compared with SHBG > 35 nmol/L. In men ≤66 years, there was no significant difference between those with sex hormone-binding globulin above or below the median (HR: 1.73, p = 0.56, reference: SHBG ≤ 35 nmol/L). TT < 12 nmol/L was associated with increased mortality in both age categories. Men >66 years with the reference combination of SHBG > 35 nmol/L and TT < 12 nmol/L (36.84%) nmol/L had significantly higher mortality than those with SHBG > 35 nmol/L and TT ≥ 12 (18.06%) and those with SHBG ≤ 35 nmol/L and TT < 12 nmol/L (13.79%). Discussion: Our data suggest sex hormone-binding globulin and total testosterone have particular impact on mortality in men aged over 66 years. Further, in older men, the combination of high sex hormone-binding globulin levels and low total testosterone is associated with greater risk than either high sex hormone-binding globulin or low total testosterone individually. Conclusions: Our findings are compatible with data suggesting the importance of sex hormone-binding globulin lies in mediating free testosterone levels.
INTRODUCTION
Men with type 2 diabetes (T2DM) suffer a mean reduction in life expectancy of 7 years (Morgan et al., 2000; Mulnier et al., 2006; Hansen et al., 2009) . A number of pathologies contribute to this phenomenon including hypogonadism (HG), which is found in about 70% of males with T2DM (Hackett et al., 2009) . HG is characterized by low serum testosterone (TT) and sexual dysfunction (Kapoor et al., 2007; Hackett et al., 2009 ) with both these factors being independent determinants of mortality (Pye et al., 2014) . Recognition of the importance of HG has led to the American Association of Clinical Endocrinologists/American College of Endocrinology guidelines on obesity (https://www.aa ce.com/files/guidelines/ObesityExecutiveSummary.pdf accessed on 04/04/2018) recommending that testosterone deficiency should be excluded in all males with T2DM. Importantly, testosterone replacement therapy (TRT) has wide-ranging beneficial effects; for example, Hackett et al. (2016a Hackett et al. ( , 2017a and Corona et al. (2017) reported improvement in erectile function, sexual desire, and other sexual parameters. Further, Corona et al. (2016) found significant reduction in body fat and increased lean mass with reduced fasting glycemia and insulin resistance. Importantly, TRT has also been associated with reduced allcause mortality in men with T2DM (Muraleedaran et al., 2013; Hackett et al., 2016b Hackett et al., , 2017b .
The recognition of the clinical importance of the association of testosterone with mortality has led to interest in the putative role of sex hormone-binding globulin (SHBG). Thus, while SHBG was considered a passive carrier of testosterone and other steroids, studies now indicate a more complex relationship between the peptide, testosterone, and health. For example, while high serum levels of SHBG are associated with increased all-cause mortality (Tint et al., 2016) , levels of the peptide are inversely associated with insulin resistance and may mediate the association between low serum testosterone and increased mortality in men with T2DM (Shores et al., 2006 (Shores et al., , 2012 Khaw et al., 2007; Muraleedaran et al., 2013; Hackett et al., 2016b) . Further, Rastrelli et al. (2018) recently reported that higher serum levels of SHBG independently of TT are associated with markers of androgen deficiency.
Both SHBG and mortality increase markedly with age (Tint et al., 2016) while testosterone levels fall (https://uroweb.org/ wp-content/uploads/EAU-Guidelines-Male-Hypogonadism-2015.pdf accessed on 04/04/2018). Accordingly, we now describe studies on the relationship between mortality, age, and SHBG. While our focus was on SHBG, we also examined its associations with TT and calculated free testosterone (cFT) as well as other variables associated with SHBG and mortality to determine whether these mediated the relationship between SHBG and mortality. Statin use was included as it is associated with reductions in CVD-related mortality (Scandinavian Simvastatin Survival Study Group, 1994) , serum testosterone (Stanworth et al., 2009), and SHBG levels (de Keyser et al., 2015) . Accordingly, first, we determined whether SHBG is associated with all-cause mortality in men with T2DM not treated with testosterone. Second, we studied the independence of this association by including SHBG and adjusting for variables associated with SHBG. As SHBG, age, and TT were independently associated with mortality, third, we examined the association between mortality and pairwise combinations of age with SHBG or TT to determine whether these influenced mortality similarly in men of different ages. Fourth, we studied associations between pairwise combinations of SHBG and TT with mortality in men aged over the median age.
PATIENTS AND METHODS

Patients
We recruited our study group from 857 men with T2DM listed in the registers of five English Midlands primary care practices screened for TT and cFT levels during April 2007-April 2009 as part of recruitment for the BLAST randomized controlled study investigating the effects of testosterone undecanoate (TU) (1000 mg) on sexual symptoms and metabolic parameters (Hackett et al., 2014) . The 364 men included in this study were selected because they had not been treated with TRT and had available SHBG measurements (362 men had both SHBG and TT data).
Each man was assessed by a clinician and considered fit for the trial. Normal or low levels of testosterone were defined as TT> or ≤12 nmol/L and cFT was > or ≤0.25 nmol/L, respectively. 
Laboratory methods
Blood samples were taken from fasting men at baseline. All analyses were carried out in a Pathology Accredited NHS Laboratory and were subjected to daily internal and regular external blind assessment of accuracy and precision. TT was measured using the validated Roche immunoassay. The reference range for adult males for this method was 210-810 ng/dl (7.3-28.1 nmol/ L) and between-run CV averaged 4.6%. cFT was estimated using the equation of Vermeulen et al. (1999) . Serum SHBG, albumin, and lipids were analyzed using a Roche Modular automated analyzer (Roche Diagnostics, Burgess Hill, UK). HbA1c was measured in whole blood using a Tosoh G7 ion exchange high-performance liquid chromatography analyzer (Tosoh Bioscience Ltd., Redditch, UK); the method standardized using International Federation of Clinical Chemistry reference material and the results were adjusted to give derived National Glycohemoglobin Standardization Program units (%).
Statistical methods
Stata version 8 (College Station, TX) was used for statistical analyses. Baseline data were checked for normal distributions (skewness and kurtosis), and mean, standard deviation (SD), median, and interquartile range (IQR) were presented. Associations between SHBG and other variables were established by multiple regression analysis, while the Cox regression analysis with all-cause mortality as the primary end point was used to identify associations between SHBG, other related (to SHBG) variables, pairwise combinations of variables (independent variables), and mortality (dependent variable).
RESULTS
Factors associated with all-cause mortality Table 1 shows, in the 364 T2DM men, mean baseline levels of SHBG, TT, cFT, and variables recorded that were considered associated with SHBG and mortality. The mean and median ages of the total group were 64.8 and 66.0 years, respectively, although the range was wide, 22.8-88.9 years. Similarly, the range of SHBG concentrations (7.9-185.5 nmol/L) was wider than in published reference ranges for adult males (e.g., 10-57 nmol/L, Mayo Medical Laboratories: http://www.mayomedi callaboratories.com/test-catalog/Clinical+and+Interpretive/ 9285 -accessed on 04/04/2018), although the 95% range was 14-85.6 nmol/L. Stratified baseline data recorded from 320 men alive at study end and 44 deceased men (first death: 0.37 years from study start) and statin treatment details at last visit are also shown. As expected, follow-up was significantly (p < 0.001) longer in survivors (median: 4.4 years, IQR: 3.7-5.1) compared with those who died (median 2.8 years, IQR: 1.7-3.4). Median body mass index (BMI) was 30.5 kg/m 2 (IQR: 27.0-34.0).
Association of SHBG and age with mortality
In a model comprising only SHBG as an independent variable, the Cox regression analysis showed SHBG levels were significantly associated with mortality in the 364 men (HR 1.02; 95% CI: 1.01, 1.03, p < 0.001). In a separate model, age was also significantly associated with mortality (HR 1.09; 95% CI: 1.05, 1.12, p < 0.001). As SHBG and age are positively correlated with mortality as seen above and each other (linear regression, p < 0.001), we further examined the relationship between these variables by stratifying SHBG serum concentrations into quartiles (≤26.8, >26.8-≤35, >35-≤50, >50-85 nmol/L) and examining the association of each quartile with mortality Table 1 Characteristics of 364 men with T2DM and after stratification by mortality
Age ( Figure 1 The mortality rate plotted against stratified SHBG quartiles. The median age of each SHBG category together with median follow-up is shown.
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© 2018 American Society of Andrology and European Academy of Andrology (Fig. 1) . Median follow-up (range 4.1-4.5 years) was similar in the quartiles. The data show that with each increase in SHBG, the median age of each group increased as did mortality, although in quartiles >26.8-≤35 and >35-≤50 nmol/L change in mortality (11.0%,12.1%) was modest.
Association of other factors with SHBG
We examined the association of SHBG levels with variables that have been reported to be associated with SHBG and/or mortality. In linear regression analyses, models (SHBG as dependent variable) comprising each variable individually, age, TT, BMI, HbA1c, triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), at baseline and statin therapy at the end of followup were significantly associated with SHBG (Table 2) . Neither blood pressure (systolic nor diastolic) nor total cholesterol (TC) were associated with SHBG.
Survival analysis of factors associated with SHBG and mortality
We entered all the factors significantly associated with SHBG (Table 2 ) into a single Cox regression model and showed that only age, SHBG, TT, and TG were significantly associated with all-cause mortality (Table 3 ). These significant factors were then entered into a single Cox regression model (Table 4a ) and while age, SHBG, and TT were significantly and independently associated with mortality, TG only approached significance. We repeated the Cox regression analysis using a model comprising age, SHBG, and TT in 362 men (Table 4b) , and all three variables remained significantly associated with all-cause mortality. We then used the Cox regression analysis to show that in a model comprising age, SHBG, and cFT (instead of TT), all variables remained significantly associated with mortality; age (HR 1.10; 95% CI: 1.05/ 1.15, p < 0.001); SHBG (HR 1.02; 95% CI: 1.00/1.03, p = 0.013);
TT (HR 1.10; 95% CI: 1.05/1.15, p < 0.001); and cFT (HR 0.01; 95% CI: 0.00/0.76, p = 0.036).
Thus, it is interesting that age, SHBG, and TT while strongly associated with each other (p < 0.001) were also independently associated with all-cause mortality. We wished to explore this further and carried out associations between pairwise combinations of these factors and mortality.
Association between mortality and pairwise combinations of SHBG and age
We initially investigated the relationship between mortality, age, and SHBG by categorizing age and SHBG by their respective median values (age: 66 years, SHBG: 35 nmol/L) and examining the associations of different pairwise combinations of these two variables on mortality using the Cox regression analysis. The Kaplan-Meier survival plots are also shown in Fig. 2A to demonstrate the associations between age, SHBG, and survival during follow-up. We then carried out a Cox regression analysis including TT, dichotomized using a clinical HG cutoff <12 nmol/L vs. ≥12 nmol/L. Table 5a shows results using age ≤66 years/SHBG ≤35 nmol/L as reference category. The data show that no difference in mortality was observed between SHBG categories (HR 1.73; 95% CI: 0.27/11.08) in men aged ≤66 years. First, when using age ≤66 years/SHBG ≤35 nmol/L as reference category once again, we found mortality was significantly greater in the older age-group: age >66 years/SHBG ≤35 nmol/L (HR 3.90; 95% CI: 1.04/14.70) and age >66 years/SHBG >35 nmol/L (HR 9.37; 95% CI: 2.68/32.79). Second, when using age >66 years/SHBG >35 nmol/L as the reference category, the other three combinations were associated with significantly lower mortality (Table 5a ). Thus, SHBG levels ≤35 nmol/L are associated with lower mortality in men >66 years (HR 0.41; 95% CI: 0.18/0.95) compared with the reference group (age >66 years/SHBG >35 nmol/L) which was associated with the highest mortality (22.45%). The dichotomized TT included, TT<12 nmol/L, was also associated with increased mortality.
Associations between mortality and pairwise combinations of TT and age
The Kaplan-Meier survival plots are also shown in Fig. 2B to demonstrate the associations between age, TT, and survival during follow-up. Then, a Cox regression analysis was used to compare the associations of mortality with combinations of TT and age (Table 5b ). The model also included SHBG (reference category ≤35 nmol/L). TT levels <12 nmol/L were significantly associated with increased mortality in both age categories. Table 5b also shows the combination of age >66 years with TT <12 nmol/L is associated with the highest mortality of 25.0%. SHBG >35 nmol/L remained significantly associated with mortality in the model.
Associations between mortality and pairwise combinations of SHBG and TT
The above analyses demonstrate that while elevated SHBG appeared to be associated with increased mortality in men >66 years, low testosterone was associated with mortality in men above and below 66 years. Thus, when examining the effects of combinations of SHBG and TT, we restricted our cohort to men >66 years. Figure 3 (Kaplan-Meier survival plot) and Table 6 (Cox regression analysis) show, in men age >66 years, that those with the combination SHBG > 35 nmol/L and TT ≥ 12 nmol/L had significantly lower mortality (18.06%) than the corresponding men in the reference category with TT < 12 nmol/L (36.84%). Men with the other two combinations of SHBG and TT also demonstrated lower mortality than those in the reference category.
DISCUSSION
In serum, SHBG and albumin mediate levels of free testosterone. Accumulating data show associations between mortality and testosterone, TRT, and SHBG. However, the mechanism whereby SHBG mediates mortality is unclear; thus, while increased levels of SHBG are associated with increased mortality, the metabolic syndrome (MetS), a condition itself linked with increased mortality (Gami et al., 2007) , is associated with reduced serum levels of the protein (Holmboe et al., 2016) . These findings are important because T2DM is a classifying component of the MetS (Alberti et al., 2009) . We have further investigated associations between SHBG and other variables associated with mortality in men with T2DM testosterone.
Previous data (Tint et al., 2016) showing associations between SHBG and age as well as mortality have been replicated in our cohort of men with T2DM who had not received testosterone treatment. We found a clear and significant association between SHBG level and age, and Fig. 1 shows that stratifying T2DM men by SHBG quartiles results in subgroups with increasing mean ages. As expected, we found associations between SHBG and relevant variables; significant negative associations were found with HbA1c, BMI, and TG while the association with HDL-c was positive. However, no association was observed between SHBG and BP. We recognize that the observed values of these variables may be altered by treatment. Further, a negative correlation between SHBG and statin use was observed, a finding compatible with reports that statin use is associated with increased risk of T2DM (Sattar et al., 2010; Abbas et al., 2012) . The interaction of SHBG with TG appears interesting and worthy of further study. Importantly, TG levels may largely reflect untreated values as this variable is not included in primary care diabetes treatment guidelines with neither fibrate nor nicotinic treatment being recommended (https://www.nice.org.uk/guidance/cg 181/chapter/1-Recommendations#lipid-modification-therapyfor-the-primary-and-secondary-prevention-of-cvd-2 accessed on 04/04/2018). This may explain why TG was the only factor, other than age, SHBG, and TT that was associated with all-cause mortality. HbA1c, BP, TC targets are included in primary care guidelines (http://www.nhsemployers.org/-/media/Employers/Docume nts/Primary-care-contracts/QOF/2014-15/2014-15-General-Med ical-Services-contract-Quality-and-Outcomes-Framework.pdf? la=en&hash=69CF3870EB19476ECDFF3A5CBAA35F08C34E00DC accessed on 04/04/2018), and this may account for the lack of association with mortality. It is clear that increasing HDL-c using therapy has largely failed to reduce mortality (Barter et al., 2007; AIM-HIGH investigators et al. 2011) .
Previous studies show both age and SHBG are independently and significantly associated with mortality although a much detailed analysis of these associations was not included (Tint et al., 2016) . Accordingly, we stratified the men by median age (66 years) and median SHBG concentration (35 nmol/L) and examined the association between combinations of these variables and mortality. We stratified SHBG by median value because unlike TT (Hackett et al., 2016b, 2017b) , there are little data regarding associations between the serum level of the protein and pathology. Our data (Table 5 , Fig. 2a) show the percentage of men who died was greater in those aged >66 years and was highest in men aged >66 years with SHBG >35 nmol/L. Interestingly, SHBG level was not associated with mortality in men aged ≤66 years. We similarly examined the association between combinations of age (stratified by median, 66 years) and TT (stratified by 12 nmol/L, the definition of HG). Table 5 and Fig. 2b show TT <12 nmol/L was significantly associated with increased mortality in both men aged less than and greater than 66 years. Thus, TT demonstrates a different pattern of association with age and mortality to SHBG. Although SHBG and TT demonstrate different age-related associations with mortality, they are closely related, and our results may reflect an independent effect of SHBG or the influence of free testosterone. Our analysis showed that if cFT was substituted for TT, it as well as SHBG and age remained significantly associated with mortality (Table 4 footnote). We recognized that using cFT may not represent physiological reality and a study based on measured values of free testosterone would be useful.
SHBG is a predictor of mortality by a mechanism that is unclear. Serum levels of the peptide are regulated by sex hormones and influenced by other hormonal and non-hormonal factors including drugs such as statins (Rosner et al., 2010; Tint et al., 2016) . Indeed, the wide range of serum values in reference groups (e.g., 10-57 nmol/L) and our study (7.9-185.5 nmol/L) seems to us to argue against this protein having a simple, direct causative effect on mortality. Thus, we interpret the analysis of associations between mortality and dichotomized combinations of SHBG and TT (Table 6) as showing the influence of the peptide is mediated by its ability to bind the hormone, thereby reducing its free concentration. Thus, the reference category (SHBG>35 nmol/L, TT<12 nmol/L) describes the combination likely to result in the lowest levels of free hormone and the one most positively associated with mortality.
We believe this study has identified interesting associations between SHBG, age, and mortality in diabetic men not receiving testosterone but has limitations. The numbers studied did not allow analysis of larger combinations of variables, and detailed information on changes to therapy during the study was not available. It would have been interesting to determine whether TRT was more effective in men with lower serum SHBG levels as a result of potentially higher circulating FT levels. We excluded the 175 men on TRT; as there were only six deaths during the follow-up period, this would not have permitted meaningful statistics. Most of the data collected for this study were retrospective, and hence, details of baseline morbidities, smoking status, and chronic complications were not available. Such data based on Read Codes would have permitted a greater in-depth analysis of the data with impact of subgroups studied. As cause of death was provided in only 21 of the 44 men who died at the end of the study, we could not use cardiovascular disease as an outcome. Table 5 Mortality data and Cox regression analysis in T2DM men stratified by median age (66 years) and (a) median value for SHBG (35 nmol/L) or (b) TT (12 nmol/L). The analyses included SHBG and TT (when not included as stratified pairwise combination with age) as continuous variables. The unadjusted Kaplan-Meier plots (Fig. 2a,b) Further, having levels of measured, rather than cFT, would have allowed proper assessment of the role of the active moiety. Information on statin treatment was obtained at the end of follow-up. However, as the quality and outcomes Framework has been used in English primary care since 2004 with statin treatment in T2DM incentivized, we expect many patients on statins at final visit/death were treated prior to study start (Livingston et al., 2015) .
CONCLUSIONS
Our data support the work of Tint et al. (2016) showing that SHBG is associated with mortality in men with T2DM. We extended these findings showing for the first time that this association is mediated by age; it was only found in men aged >66 years. The mechanism for the association of the peptide with mortality and the influence of age is unclear though as suggested by Svartberg et al. (2014) and our analysis, may involve the mediation of free testosterone levels by SHBG. The importance of SHBG in gonadal health is indicated by Rastrelli et al. (2018) . They reported that higher levels of SHBG independently of TT are associated with markers of androgen deficiency.
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